Zentalis Pharmaceuticals

Update in progress

ZNTL (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule cancer therapies in the United States. It develops azenosertib, in Phase 3 for ovarian cancer and other tumors, and ZN‑c3‑001, a Phase 1 study of azenosertib as monotherapy in solid tumors. MAMMOTH (ZN‑c3‑006) tests azenosertib in PARP-inhibitor–resistant ovarian cancer (Phase 1/2). It has a licensing relationship with Recurium IP Holdings and was founded in 2014 in San Diego.

Company score

Sentiment: -0.48; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.13; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive